PRESS RELEASE

Biom’up announces first US sales in laparoscopy for HEMOBLAST™ Bellows and the signing of an exclusive distribution agreement for HEMOBLAST™ Bellows in Australia

Saint-Priest, France, April 15th, 2019 – 8h00 (CET) – Biom’up SA (the “Company »), specializing in surgical hemostasis, announces today first sales on the US market of its HEMOBLAST Bellows Laparoscopic Applicator. Successful launch of the HEMOBLAST Bellows Laparoscopic Applicator in the US, first sales booked in March 2019 Major framework…

READ

Biom’up appoints George Makhoul as Chief Commercial Officer (USA)

Saint-Priest, France, January 31, 2019 – 8h00 (CET) – Biom’up (the « Company »), specializing in surgical hemostasis, today announced the appointment of George Makhoul as Chief Commercial Officer with responsibility for the United States, effective today. Mr. Makhoul has a track record in commercializing medical products to hospitals and surgeons combined…

READ

Biom’up HEMOBLAST™ Bellows full pivotal trial results published in Journal of Cardiac Surgery

Saint-Priest, France, January 30, 2019, 8:00 am (CET) – Biom’up (the “Company”), a specialist in surgical hemostasis, today announced the publication of scientific and clinical data with the Company’s lead product HEMOBLAST Bellows, a hemostatic product to control bleeding in a broad range of both traditional and laparoscopic surgical procedures…

READ

Biom’up granted FDA approval for its HEMOBLAST™ Bellows Laparoscopic Applicator

Saint-Priest, France, January 22, 2019, 8:00 am (CET) – Biom’up (the “Company”), specializing in surgical hemostasis, has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its HEMOBLAST Bellows Laparoscopic Applicator for all minimally-invasive procedures. Biom’up submitted the premarket approval (PMA) supplement to the FDA…

READ

Achievement of two major development milestones

Saint-Priest, France, January 7, 2019, 8:00 am (CET) – Biom’up (the “Company”), a specialist in surgical hemostasis, today announces an IDE (Investigational Device Exemption) application submitted to the FDA for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate for managing minimal and mild levels of bleeding…

READ

Biom’up sees a strong commercial uptake in HEMOBLAST™ Bellows in the US and Europe

Saint-Priest (France), November 28, 2018, 8:00 am (Paris time) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces today an update on its first months of commercialization of HEMOBLAST Bellows in the US and Europe and confirms a strong uptake among hospitals and surgeons. HEMOBLAST Bellows now used in…

READ

Biom’up announces completion of the 2018 scale-up of its manufacturing facility to meet commercial demand for HEMOBLAST™ Bellows

Saint-Priest (France), November 08, 2018, 8:00 am (Paris time) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces today the completion of the 2018 scale-up of its manufacturing facility to meet commercial demand for HEMOBLAST™ Bellows, in the US and selected national markets in the EU. 2018 scale-up of…

READ

Biom’up completes its Board of Directors with the nomination of Dr. Peter Byloos to support its international growth

Dr. Byloos possesses solid experience in the healthcare sector. Currently CEO of Optegra Eye Health Care, a UK based eye treatment company, he previously served as CEO and President of Handicare, the specialized Norwegian equipment provider for the elderly and disabled and has occupied several International Leadership positions with CR…

READ

Biom’up present at the 8 th Strategic Council of Health Industries hosted by France’s Prime Minister

An illustration of Biom’up’s first achievements and growing position in international markets Significant growth of the number of U.S. hospitals undergoing a medical-economic evaluation of HEMOBLASTTM Bellows A strengthened sales force in the United States

READ

Biom’up obtains CE Mark for its HEMOBLASTTM Bellows Laparoscopic Applicator

An additional device designed to deliver the HEMOBLAST Bellows powder in minimally-invasive procedures Biom’up ready to address a new European market segment where traditional hemostatic products are generally difficult to use or unusable Yet another important milestone enabling Biom’up to address a new market of approximately 500,000 surgeries per year…

READ

Caution: Federal law restricts this device to sale on or by the order of a physician. The trademark of HEMOBLAST™ Bellows and SPOT GRADE™ are the property of Biom’up. The trademarks of the products listed herein are trademarks of their respective manufacturer. Please refer to the Instructions for Use accompanying each device for further information. The presentation contains pictures owned by third party and remains their property.
E-MR-318-V1
HEMOBLAST™ Bellows Hemostatic Agent [instructions for use: E-MR-217-V6]